# TriLink BioTechnologies

Maravai LifeSciences子公司——全球领先mRNA CDMO，为mRNA疫苗、治疗和研究提供CleanCap帽类似物和GMP级mRNA组分；临床项目交期和MOQ最短。

Source: https://cn.bioecon.ru/companies/trilink/
Updated: 2026-06-19

- 国家: United States
- 营收: ~$100M
- 员工: ~500 emp

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 成立 | 1996年 | https://www.trilinkbiotech.com/about-us/ |
| 生产基地 | 加利福尼亚州圣地亚哥（多处园区）及佛罗里达州Jupiter | https://investors.maravai.com/news-events/press-releases/detail/128/trilink-opens-gmp-enzyme-manufacturing-facility-enabling-integrated-ivt-supply-from-rd-to-commercial-scale, https://sdbj.com/real-estate/commercial/trilink-biotechnologies-expands-campus/, https://www.trilinkbiotech.com/press-releases/trilink-biotechnologies-announces-new-san-diego-facility-for-late-phase-mrna-drug-substance-production |
| 产能 | mRNA生产能力为每批1克至100克以上；圣地亚哥118,000平方英尺生产设施；佛罗里达州Jupiter的5,000平方英尺GMP酶设施 | https://investors.maravai.com/news-events/press-releases/detail/44/maravai-lifesciences-offers-end-to-end-mrna-production-with-the-launch-of-trilink-biotechnologies-plasmid-dna-manufacturing-services, https://www.trilinkbiotech.com/, https://www.trilinkbiotech.com/press-releases/trilink-biotechnologies-announces-new-san-diego-facility-for-late-phase-mrna-drug-substance-production |
| 认证 | 符合ISO 9001:2015与ICH Q7的质量体系 | https://www.trilinkbiotech.com/, https://www.trilinkbiotech.com/about-us/ |
| 营收 | $1.198亿（截至2025年12月31日的财年） | https://investors.maravai.com/news-events/press-releases/detail/123/maravai-lifesciences-reports-fourth-quarter-and-full-year-2025-financial-results, https://investors.maravai.com/sec-filings/all-sec-filings/content/0001823239-26-000011/0001823239-26-000011.pdf, https://www.sec.gov/Archives/edgar/data/1823239/000182323926000005/exhibit991-q42025.htm |

独立来源: investors.maravai.com, sdbj.com, sec.gov

## 技术

- [mRNA 平台与 LNP 递送](https://cn.bioecon.ru/technology/mrna-platforms-lnp-delivery/)
- [先导编辑](https://cn.bioecon.ru/technology/prime-editing/)